On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now Blog

Stocks on Radar

The Reg A Conference 2023: Inspiration, Innovation, and Immersive Networking

Reg A sponsors and management, marketing consultants, structured finance investors, and deal advisors – all are invited to join The Reg A Conference June 30, 2023 at the Westchester Country Club in Rye, New York. This high-energy conference will bring private companies and finance experts together to promote discussion that can lead to deal making and to provide in-depth education regarding the increasingly popular Regulation A as a capital raising tool.

For executives and investors looking to raise capital at reduced cost – without leaping through the regulatory hoops of a traditional IPO – The Reg A Conference provides insight and education from thought leaders with years of experience at companies like Deloitte, Ernst & Young, Morgan Stanley, Woodruff Sawyer, and many more, along with unmatched opportunities to network with experts who get deals done.

Brought to you by DealFlow Events, The Reg A Conference offers unparalleled investment opportunities while attendees enjoy a comfortable environment for doing business, featuring indoor and outdoor event spaces in luxurious surroundings.

Expert speakers and panelists have deep experience in Regulation A offerings and will provide valuable insight into how they work: what’s involved, the rules, timelines, fees and case examples of actual results.

Connecting the Reg A community

Since its inception in 2015, Regulation A provides an indemnity from registration obligations for businesses that want to raise money through a public offering of securities. Regulation A has two tiers of public offerings. Each tier involves different reporting needs, as well as separate limits for the value of securities that can be sold in any given year. It is one of the most cost-effective ways of raising capital that small to medium-sized businesses can use to ramp up their growth and accelerate their success.

You don’t want to miss out.

To learn more, visit https://ibn.fm/n2LIh

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields Most Convincing Evidence for Anti-Inflammatory Actions of CBD with its DehydraTECH(TM)-CBD

  • Lexaria just announced additional findings from its HYPER-H21-4 human clinical study, highlighting significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease
  • This has been termed as “the most convincing evidence in humans,” ultimately showcasing the potential of the company’s patented DehydraTECH(TM)-processed CBD
  • Other third-party research studies have failed to demonstrate a sustained decrease in resting blood pressure with oral CBD dosing. More so, none have yielded evidence of the anti-inflammatory actions of CBD until Lexaria’s HYPER-H21-4 human clinical study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its HYPER-H21-4 human clinical study that sought to explore the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) in reducing blood pressure (“BP”). Of note was the demonstration of significant reductions in several pro-inflammatory biomarkers associated with cardiovascular disease (“CVD”) in what was described as “the most convincing evidence in humans” of the anti-inflammatory actions of CBD.

“There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” noted Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of Study HYPER-H21-4 (https://ibn.fm/Cx0nx).

This finding adds to the success of the ambitious HYPER-H21-4, which successfully met all primary efficacy and safety objectives, with resting BP showing a significant reduction among hypertensive patients. Furthermore, this reduction in BP was sustained over a full 5-weeks of dosing, with no serious adverse events reported.  This built on the findings from the four previous human clinical studies conducted from 2018 to 2022, all of which have paved the way for Lexaria’s anticipated U.S. Food and Drug Administration (“FDA”) HYPER-H23-1 clinical study, its most ambitious yet.

Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” HYPER-H23-1 looks to build on all previous studies conducted by Lexaria thus far. It also plays an integral role as a lead-up to IND filing this summer, with hopes for FDA authorization within 60 days after that.

So far, only a handful of other research studies have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing. However, none have been successful at achieving it. More so, none have yielded evidence of the anti-inflammatory actions of CBD, which shows the potential of Lexaria’s DehydraTECH-CBD.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

DGE’s 11th Advancing Women’s Leadership in Pharma & Healthcare Event

DGE invites business executives, women entrepreneurs, aspiring professionals, and industry leaders, to attend the 11th Advancing Women’s Leadership in Pharma & Healthcare event, to be held at The Bellevue Hotel, Philadelphia, PA, from September 19 – 21, 2023. The 11th edition of this transformative event provides an important platform to promote women’s empowerment.

The highly anticipated Advancing Women’s Leadership in Pharma & Healthcare event is dedicated to fostering gender diversity in male-dominant industries. This impactful and inspiring conference will feature an attractive lineup of keynote speakers and business leaders who will organize interactive workshops, sessions, and networking opportunities.

The event will feature thought-provoking case studies that will emphasize the success stories of women leaders. Attendees will get insights into the unique opportunities and challenges women often face in the healthcare and pharma industries. Esteemed business leaders and industry experts will share information on topics such as career development, leadership, mentorship, and diversity in the workplace.

Shaping the Future with Women’s Empowerment

The event aims to provide a holistic approach to professional growth while providing women with the skills, support, and tools they need to overcome business challenges and obstacles. The keynote presentations will reveal the key strategies to ensure business success and resilience in the pharmaceutical and healthcare sectors.

Focused on driving women’s careers, the skill-building workshops and hands-on sessions will focus on practical techniques for conflict resolution, effective negotiation, and women empowerment. By sharing personal experiences, influential business leaders will provide actionable strategies to drive change and handle key issues related to gender equality, diversity, and inclusion.

Offering a unique platform to connect and inspire, the 11th Advancing Women’s Leadership in Pharma & Healthcare event recognizes the importance of networking with industry leaders. The emerging women entrepreneurs will get expert guidance from veteran leaders and mentors. Attendees will get an opportunity to connect with business leaders and thrive in an environment of professional growth and knowledge sharing.

To learn more, please visit https://ibn.fm/nIBgE.

The SPAC Conference 2023: Meet Quality Companies Poised for Growth

SPAC executives, brokerage firms, institutional investors, investment bankers and fund managers are invited to attend the SPAC Conference 2023 presented by DealFlow Events, to be held at the Westchester Country Club, Rye, New York from June 28-29, 2023.

As the largest forum for networking and discussion of special purpose acquisition companies, The SPAC Conference 2023 delivers the most reliable and up-to-date information required to thrive in the challenging SPAC market. The conference includes a private meeting space available throughout the event for company executives interested in consulting with institutional investors and management teams.

For private companies considering going public via a SPAC merger, the SPAC Conference 2023 will offer an unmatched opportunity to network with the leading deal-makers in the business. At this two-day event, key advisors, private equity firms, and corporate management teams will get an inclusive update on the state of the market from industry leaders.

Paving the Way to Growth Capital and Liquidity

The SPAC process continues to be an effective way to take a developing company public while avoiding the complications and costs associated with a traditional IPO. This is especially true today due to investor uncertainties created by a rapidly shifting equities market. SPACs continue to represent an important opportunity for those who know how best to utilize them. The SPAC Conference delivers cutting-edge insights into how to use this opportunity to meet your investment liquidity or corporate growth objectives.

Offering the largest gathering of management teams, investors, and bankers, this best-in-class conference includes one-on-one meetings that attendees can easily schedule through their event app, enabling participants to connect with SPAC experts before the event even starts, then converse face-to-face in private meeting areas. Conference-goers can count on the best networking opportunities to maximize their business development in the luxurious setting of the Westchester Country Club.

Our conference agenda, which includes the full line-up of speakers scheduled to present, is now available at https://spacconference.com/agenda/. The list includes industry leaders and executives from such companies as Deloitte, Loeb & Loeb, Withum, Laurel Hill, and Woodruff Sawyer.

To learn more, visit https://ibn.fm/NSIzp.

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Targets Leadership Position in Multi-Billion Dollar Green Ammonia Industry with $7.5 Million Private Placement

  • FuelPositive recently announced a non-brokered private placement to raise up to $7.5 million, which is active now
  • According to the company, net proceeds from the placement will be directed toward further development of demonstration systems for its on-site green ammonia production systems as well as working capital requirements
  • As of early May, commissioning of the first farm-ready demonstration unit was nearing completion, with the company having kicked off production of its first commercial systems
  • FuelPositive will deliver the demonstration system to a farm in Manitoba, Canada, and expects to gather real-time usage data that will shape future systems being built concurrently with the initial demonstration system

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a green technology company committed to developing commercially viable and sustainable onsite containerized green ammonia production systems, announced plans to raise up to $7.5 million by way of a non-brokered private placement. The net proceeds from this placement, the company said, will be channeled toward further development of demonstration systems for its green ammonia production solution, general working capital, and payment of services provided to FuelPositive in the ordinary course of business (https://ibn.fm/0ozaW).

“We anticipate that the enhanced liquidity resulting from this offering will contribute to greater growth for the company. The company’s pioneering green ammonia technology and decentralized business model hold immense potential to reshape the ammonia industry, fostering a greener future for generations to come. The net proceeds from this financing will help ensure FuelPositive’s leadership and ‘first-mover’ position in the multi-billion dollar sustainable and green ammonia industry,” said Ian Clifford, FuelPositive’s Board Chair and CEO.

The placement will consist of up to 115,384,615 units of the company, each priced at $0.065. Each unit comprises one common share of the company and one common share purchase warrant, allowing holders to purchase an additional common share at an exercise price of $0.09 within 36 months following the closing date of the placement. If the volume-weighted average closing price of FuelPositive’s common shares on the TSX Venture Exchange exceeds $0.40 for ten consecutive trading days, FuelPositive may choose to accelerate the expiry date of the warrants to 30 days after a public announcement of the election.

According to Clifford, the placement incorporates the newly implemented Listed Issuer Financing Exemption (“LIFE”), allowing both accredited and non-accredited investors to participate equally in the company’s financings. FuelPositive also announced that the securities issued in the placement pursuant to LIFE would not be subject to a hold period per Canadian securities law, while all other securities would be subject to a statutory hold period of four months and one day following issuance.

The upcoming placement is expected to support FuelPositive’s efforts to revolutionize the green ammonia industry by commercializing production solutions to produce green ammonia when and where it’s needed. Already, the company has begun running the final commissioning of the first farm-ready demonstration system, a production unit capable of producing300 kg per day of green anhydrous ammonia or a little over 100 metric tons per year, according to a May 2 news release (https://ibn.fm/g2lvf). Aptly named the FP300 model, this system is set to be delivered to the 11,000-acre crop farm of Tracy and Curtis Hiebert, where it will be heavily monitored for a full year, with the results shaping future systems being built concurrently with the initial demonstration system.

FuelPositive’s partnership with the Hieberts also includes a provision that may see the company piloting up to three versions of the demonstration systems on the farm (https://ibn.fm/SjRCq). The planned financing will, therefore, be integral in helping the company achieve this and other targets.

In addition to reporting that the final commissioning is underway, FuelPositive also announced it had started production of its first commercial systems. Having successfully met its planned pre-sales capacity of 30 units, the company plans to deliver the first batch of FP300 commercial systems beginning in 2024.

FuelPositive also announced its latest model, the FP1500, a turnkey system that upsizes the daily output of green anhydrous ammonia to 1,500 kg. or 500 metric tons per year.   According to the company, the decision to offer this larger system was influenced by customer demand from its pre-sales campaign. “Multiple end-users in various sectors, including farms of 10,000+ acres, have indicated the immediate need of FuelPositive systems of this scale and configuration. The FP1500 will answer this larger scale, onsite need,” explained Clifford.

For more information, visit the company’s website at www.FuelPositive.com.

NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

D-Wave Quantum Inc. (NYSE: QBTS) CEO Believes in Importance of Adopting Quantum Mindset Amid Today’s Complex Business Environment

  • Quantum computing can be a tool to help enterprises navigate the ongoing disruption and complexity of today’s business world
  • Quantum adoption is expected to grow substantially over next 15-30 years, practical quantum solutions are already here, and demand for quantum-ready talent is rapidly accelerating
  • Governments around the world have developed quantum adoption and investment strategies

As businesses encounter challenging computational problems that classical computers are ill-equipped to solve efficiently, or at all, the value of quantum computing is becoming increasingly apparent. Quantum can be used to tackle data-intensive computations in the areas of logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection, financial modeling, and more, and businesses are planning to increase their near-term commitments to this nascent technology, per research from Hyperion Report.

In this context, business leaders should embrace a “quantum mindset” in order to more effectively navigate today’s ongoing disruptions and complexity, according to D-Wave Quantum (NYSE: QBTS) President and CEO Dr. Alan Baratz. In a recent article published on LinkedIn entitled Shifting to Quantum Mindset: Why the Time is Now, Baratz explains why he believes quantum computing is here to stay. He outlines how quantum computing is progressing on multiple fronts, generating significant market potential and talent demand, amid increasing business and government investments in the technology on a worldwide basis (https://ibn.fm/kNSo5).

“The imperative is to adopt a quantum mindset that is ever-present,” Baratz states. “Now is the time to bring quantum to the forefront of decision-making when it comes to tech investment, business operations, national and global competitiveness, and workforce development.”

With quantum popularity increasing, so does the need for talent capable of working with it. Although quantum physicists are a part of the rapidly developing technological landscape, anyone with a computer science background who can code in Python can get started working with quantum.

As various governments map out national quantum strategies and increase funding, they are also targeting quantum education and building quantum-hybrid solutions to solve public sector challenges. Countries including the UK, Canada, France, and India have recently shared updated quantum strategies that map out adoption and investment plans, showing their long-term commitments to the technology.

According to Boston Consulting Group, the quantum computing market will grow to between $450 billion and $850 billion over the next 15 to 30 years (https://ibn.fm/ZKwEn). Hyperion Research estimates that 80% of quantum early adopters are planning to increase their commitment to quantum in the next two or three years, with one-third of them expected to invest at least $15 million in quantum (https://ibn.fm/n2aGv).

D-Wave is working with customers to build commercial quantum-hybrid applications today. D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used by some of the world’s most advanced enterprises. These customers include blue-chip industry leaders such as Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, NEC Corporation, Pattison Food Group, DENSO, and Lockheed Martin.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding the release and performance of the Advantage2 processor. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Provides Viable Renewable Energy Solutions That Reduce Methane Emissions

  • Methane is believed to cause climate change by trapping 86 times more heat in the atmosphere than carbon dioxide
  • EVGIF advances RNG technology that negates the effects of methane while combatting carbon dioxide production caused by burning natural gas
  • The RNG production process produces biogas that can be refined and purified to create pipeline-quality RNG, which can be injected into current networks
  • EverGen aims to create an RNG network comprising 20+ facilities across Canada within five years

Methane is released while producing and transporting coal, natural gas, and oil. As a result, climate justice activists believe methane causes climate change by trapping 86 times more heat in the atmosphere than carbon dioxide alone (https://ibn.fm/M80Wk). Fortunately, EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), a Canadian renewable energy company, offers a solution through renewable natural gas (“RNG”) technology that negates the effects of methane while combatting carbon dioxide production associated with burning natural gas.

Experts from the World Economic Forum believe that methane emissions must drop to reach climate goals (https://ibn.fm/bErq9). According to the organization, methane emissions caused roughly 30% of global temperature increases since industrialization, and the problem is getting worse as emissions reach record levels.

RNG technology provides a solution that is more than just carbon-neutral – it’s carbon negative due to its ability to remove methane that otherwise would be produced when organic matter decomposes. The RNG production process leverages a process called anaerobic digestion that uses microorganisms to break down organic materials such as sewage sludge, organic waste, and animal manure in an enclosed, oxygen-free container (https://ibn.fm/FZe1A). The process then creates two primary products: digestate – a by-product that can be used as crop fertilizer, and biogas – a renewable source of methane gas.

Biogas can be refined and purified to create RNG – a pipeline-quality gas that can be injected into existing networks. EverGen aims to develop such a network comprising 20+ facilities within five years by acquiring, managing, and developing RNG and waste-to-energy projects nationwide.

Current projects in the company’s portfolio include Fraser Valley Biogas, Sea to Sky Soils, and Net Zero Waste Abbotsford in British Columbia, and a 67% stake in Alberta-based GrowTEC. Across the country in Ontario, EverGen has a 50% stake in Project Radius – a portfolio of three large, on-farm, and late-stage development projects that can potentially produce up to 1.7 million GJ of RNG annually.

The company is based in British Columbia – a province that actively takes action to reduce overall greenhouse gas emissions by supporting projects that displace equivalent volumes of traditional natural gas with carbon-neutral RNG. “The more RNG we have, the less conventional natural gas we need,” said Jenelle De La Cour, a manager of renewable gas accounts with FortisBC (https://ibn.fm/cr9bd). “Every RNG project is a win for climate action.”

EverGen leads RNG adoption in Canada with a portfolio of carbon negative RNG projects across the country. The company is committed to unlocking the power of carbon negative RNG to combat climate change, improve sustainability, and help reach worldwide emission targets.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) To Play Key Role in North American Push to Control its Rare Earth Critical Metals Destiny

  • Canada-based Ucore Rare Metals Inc. is preparing to begin construction on a rare earth element (“REE”) processing plant in Louisiana that it says will be the first REE separation facility to operate at commercial scale in North America
  • Currently, China dominates both REE feedstock supply and REE processing capacity on a global basis, generating concerns that it can control the world’s ability to build modern technologies and use its control to retaliate against countries in adversarial situations
  • Modern technologies that rely on REEs for crucial magnets in their composition include phones, computers, household appliances, electric vehicles, solar panels, and wind turbines
  • Ucore plans to provide 2,000 metric tons of total rare earth oxides (“TREOs”) annually by late next year, increasing that amount to 5,000 metric tons in 2026

Critical metals production innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is accelerating its efforts to establish a North American-focused supply chain for rare earth elements (“REEs”) since announcing in April that it had reached an agreement to lease an 80,800 square-foot brownfield facility in Alexandria, Louisiana for its first Strategic Metals Complex (“SMC”) facility for REE separation and oxide production.

The company has strengthened its financial position and is working to fulfill plans to launch construction of the Louisiana SMC this year, building to a production capacity of 2,000 metric tons of total rare earth oxides in 2024 and increasing it to 5,000 metric tons in 2026.

Rare earths are vital to many computerized application processes and, though plentiful around the world, tend to make up a small portion of the ores they are found in, requiring a labor-intensive methodology for extracting the REEs.

“It is critical that the United States leads in establishing the critical metals supply chain essential to a changing manufacturing landscape across North America,” Ucore Chairman and CEO Pat Ryan stated in an April 6 company news release (https://ibn.fm/JziR4). “The establishment of the Louisiana SMC in Alexandria represents one of these first building blocks and a significant contributor to the shift toward energy production and consumption diversification.”

China’s dominance of the REE production industries has created concerns in other nations about a potential monopoly on the market by the Asian behemoth. Two years ago, the country consolidated three of its dominant “Big 6” rare earth state-owned enterprises (“SOEs”) into one mega-conglomerate, which now controls up to a quarter of global mineral-bearing REEs and nearly two-thirds of the heavy rare-earth supplies within the country (https://ibn.fm/YQ3Rl). And China also operates roughly 60 percent of world REE production (https://ibn.fm/nq94g), allowing it to weaponize its resources when it wishes to maintain control in international conflicts.

“These minerals power phones and computers, household appliances, electric vehicles and batteries, solar panels, wind turbines, and so much more,” President Biden stated in February (https://ibn.fm/w8iNY). “When it comes to clean energy, China has spent years cornering the market on many of the materials that power the technologies that we rely on. … We can’t build a future that’s made in America if we ourselves are dependent on China for the materials that power the products of today and tomorrow.  And this is not anti-China or anti anything else; it’s pro-American.”

Ucore’s Louisiana facility is expected to use the company’s 100 percent-owned Rapid SX (TM) technology, which has already been successfully piloted in Canada, to operate North America’s first rare earths separation facilities at scale.

“Absolutely we’re behind,” Special Presidential Coordinator Amos Hochstein said in a CNBC interview (https://ibn.fm/J1zOE). “We have to recognize that we have not invested, and that’s what the United States is trying to do now. … We have to learn from what we went through in the oil and gas energy space, as we transition to a new energy market that relies still on natural resources.”

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

DGE’s 4th Annual Clinical Trial Agreements Forum: Reduce Bottlenecks and Expedite Contracting Timelines

Clinical research, contract specialists, clinical operations, regulatory affairs, and legal strategists will all convene at Dynamic Global Events’ (“DGE’s”) 4th Clinical Trial Agreements Forum, returning to in-person learning on August 29-30 in Philadelphia, PA. As the only industry forum to specifically focus on Clinical Trial Agreements (‘‘CTAs’’), this will be a must-attend for legal, regulatory, and clinical contracting professionals who want to stay ahead of the curve on the latest strategies to overcome the industry’s most pressing challenges.

The two-day conference is designed to provide a unique networking and learning experience on the key insights and the latest trends, best practices, and most critical factors impacting the effectiveness and efficiency of your Clinical Trial Agreements. Attendees will enrich their knowledge of how best to structure CTAs that safeguard clinical data in today’s constantly evolving ecosystem—and walk away armed with actionable strategies to expedite timelines and achieve contracting success.

Offering both in-person registrations to maximize networking opportunities and possibilities for organizational improvement, and virtual format to attend for those who cannot make it on-site. On-demand access will also be available to watch the recording of the full conference as well.

No other conference goes into as much detail on these timely and crucial topics:

  • Explore CTAs in the Context of DCTs and Remote Monitoring
  • Key Considerations for CTA Drafting to Avoid Uninsured Losses
  • Accelerate Indemnification Clause Negotiations and Timelines
  • Protect IP Rights and Prioritize Data Confidentiality
  • Create and Negotiate Master Budgets to Reduce Bottlenecks
  • Deep Dive into GDPR: Clarifications and Impact on CTAs
  • Structure Patient Injury Language in Subcontracts
  • Unravel Difficulties Surrounding Investigator-Initiated CTA clauses
  • Effectively Reach Consensus Between Sponsors, Sites, and CROs

Key Takeaways:

DGE’s 4th conference focuses specifically on the most critical challenges surrounding Clinical Trial Agreements and how to overcome them.

  • Professional speakers from a wide variety of disciplines and backgrounds—including biopharma, research sites, academia, legal experts, and many more luminaries
  • Located in the comfortable and beautiful city of Philadelphia, at the ‘Inn at Penn’, a Hilton Hotel
  • Registration is available for in-person or virtual attendance

Behind the scenes:

Dynamic Global Events manages a wide-ranging portfolio of educational gatherings for professionals in the life sciences, utilizing in-person, virtual, and hybrid access capabilities. Its content-driven team provides narrowly focused opportunities for professionals by engaging experts who can address specific challenges and help to develop strategies for creating success.

DGE’s customer-first culture helps life sciences professionals differentiate between content and commercialism while promoting the exchange of critical information between life science professionals and suppliers who support shared goals.

For more information about this event, please visit https://ibn.fm/6ZQEr.

Web3 Berlin Conference: Pioneering the Future of Cryptocurrency

Blockchain technology experts, crypto enthusiasts, investors, and business owners are invited to attend the Web3 Berlin Conference to be held in Berlin, Germany, June 10-11, 2023. As the technological world is on the verge of evolution, the much-awaited Web3 Berlin Conference is set to unveil the potential of associated disruptive technologies.

Hosting the prominent gathering of unique ideas and intellectual minds, Web3 Berlin Conference promises to celebrate technological innovation. The conference has a rich history of successful events, featuring engaging workshops and immersive panel discussions.

The keynote speakers will share insights into blockchain technology, decentralized applications (dApps), decentralized finance (DeFi), and non-fungible tokens (“NFTs”). Attendees will get a unique opportunity to meet visionaries who will share their expertise about decentralized technologies investment opportunities, industry trends, and regulatory challenges.

A Groundbreaking event for Networking and Social Gathering

Web3 Berlin Conference will feature industry pioneers and renowned industry leaders who will share interactive sessions about the latest frameworks, tools, and methodologies for creating decentralized applications. Blockchain developers will get an opportunity to hone their skills and gain valuable insights into real-world projects.

The exhibition area of the conference will feature prominent blockchain companies and startups that will demonstrate the latest industry advancements. By providing ample networking and collaboration opportunities, this dynamic event will enable attendees to launch their innovative projects. Moreover, the Web3 ecosystem will provide them with an opportunity to meet like-minded individuals and crypto investment prospects.

The 2023 Web3 Berlin Conference is designed to nurture an inclusive community, forging new partnerships while driving the global acceptance of Web3 technologies. Interested participants can register now to avail early-bird rates and secure their spot at the epitome of the Web3 revolution.

To learn more, please visit https://ibn.fm/5mTk0.

From Our Blog

The Reg A Conference 2023: Inspiration, Innovation, and Immersive Networking

June 9, 2023

Reg A sponsors and management, marketing consultants, structured finance investors, and deal advisors – all are invited to join The Reg A Conference June 30, 2023 at the Westchester Country Club in Rye, New York. This high-energy conference will bring private companies and finance experts together to promote discussion that can lead to deal making […]

Rotate your device 90° to view site.